SonoScape Medical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Kunxiang Wu

Algemeen directeur

CN¥900.0k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Oct 28

Investors Appear Satisfied With SonoScape Medical Corp.'s (SZSE:300633) Prospects As Shares Rocket 28%

Oct 21

These 4 Measures Indicate That SonoScape Medical (SZSE:300633) Is Using Debt Reasonably Well

Sep 20

Weak Statutory Earnings May Not Tell The Whole Story For SonoScape Medical (SZSE:300633)

Sep 04

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Aug 18

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Jul 17

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Feb 28

CEO

Kunxiang Wu (61 yo)

no data

Tenure

CN¥900,000

Compensatie

Mr. Kunxiang Wu is General Manager & Director of SonoScape Medical Corp.

SonoScape Medical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

Less than half of directors are independent

SonoScape Medical Corp. Approves Board Elections

Insufficient new directors

SonoScape Medical Corp. Announces Executive Election

Recent updates

SonoScape Medical Corp. Just Missed Earnings; Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 23% overvalued

Investors Appear Satisfied With SonoScape Medical Corp.'s (SZSE:300633) Prospects As Shares Rocket 28%

Investor sentiment deteriorates as stock falls 19%

SonoScape Medical Corp. to Report Q3, 2024 Results on Oct 26, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

These 4 Measures Indicate That SonoScape Medical (SZSE:300633) Is Using Debt Reasonably Well

Weak Statutory Earnings May Not Tell The Whole Story For SonoScape Medical (SZSE:300633)

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

SonoScape Medical Corp. to Report First Half, 2024 Results on Aug 29, 2024

Does SonoScape Medical (SZSE:300633) Have A Healthy Balance Sheet?

Dividend increased to CN¥0.32

SonoScape Medical Corp. 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024

Pinning Down SonoScape Medical Corp.'s (SZSE:300633) P/E Is Difficult Right Now

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 7.8% to CN¥50.15

Full year 2023 earnings: EPS misses analyst expectations

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp. to Report Q1, 2024 Results on Apr 27, 2024

We Think SonoScape Medical (SZSE:300633) Can Manage Its Debt With Ease

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Less than half of directors are independent

Investor sentiment improves as stock rises 17%

SonoScape Medical Corp. Approves Board Elections

SonoScape Medical Corp. to Report Fiscal Year 2023 Results on Apr 12, 2024

Price target decreased by 8.0% to CN¥57.34

Now 21% undervalued

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.4% to CN¥62.43

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape Medical Corp. to Report Q2, 2023 Results on Aug 23, 2023

SonoScape Medical Corp. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 08 June 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

Price target increased to CN¥71.16

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.076 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Sonoscape Medical Corp. Announces Final Dividend on Share A for 2021, Payable on July 15, 2022

SonoScape Medical Corp. Approves 2021 Profit Distribution Plan

SonoScape Medical Corp. Proposes Final Cash Dividend for 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape S-Fetus 4.0 Release to Simplify Sonography Process

SonoScape Medical Corp. Receives FDA 510(k) Clearance for HD-550 Endoscopy system

Third quarter 2021 earnings released: EPS CN¥0.076 (vs CN¥0.004 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.085 in 2Q 2020)

SonoScape Obtains CE-Mark for Its Linear Array Echoendoscope EG-UC5T

Price target increased to CN¥30.86

Sonoscape Medical Corp. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.02 loss in 1Q 2020)

New 90-day low: CN¥20.36

SonoScape Medical Corp. Announces Executive Election

New 90-day low: CN¥21.50

New 90-day low: CN¥25.16

Third quarter earnings released

SonoScape Medical Corp. announced that it expects to receive CNY 1.2 billion in funding

New 90-day low: CN¥27.25